open access

Vol 1, No 1 (2013)
Original article
Published online: 2013-07-11
Get Citation

Enhanced antiplatelet effect of enteric- -coated acetylsalicylic acid in co-administration with pantoprazole

Michał Kasprzak, Marek Koziński, Katarzyna Stankowska, Joanna Boinska, Katarzyna Linkowska, Wioleta Stolarek, Agata Marciniak, Tomasz Fabiszak, Eliano Pio Navarese, Jacek Budzyński, Leszek Popiołek, Tomasz Grzybowski, Danuta Rość, Grzegorz Grześk, Przemysław Paciorek, Jacek Kubica
Folia Medica Copernicana 2013;1(1):5-11.

open access

Vol 1, No 1 (2013)
ORIGINAL ARTICLES
Published online: 2013-07-11

Abstract

Background. Proton pump inhibitors (PPI) are recommended for patients receiving antiplatelet therapy.Several studies have revealed that PPI may attenuate the antiplatelet effect of ASA. However, our pilot study has indicated a positive interaction between pantoprazole and enteric-coated aspirin.The aim of the current study was to confirm that pantoprazole enhances the antiplatelet effect ofenteric-coated aspirin in patients with acute coronary syndrome (ACS) treated with dual antiplatelettherapy. Moreover, the influence of CYP2C19 polymorphism on the antiplatelet effect of aspirinwas assessed.

Material and methods. Ninety three consecutive ACS patients were prospectively enrolled in a randomized, crossover, open-labeled study. Forty four patients were given orally 40 mg of pantoprazole for the initial fourdays while the remaining forty nine were treated with pantoprazole from the 5th to the 8th day of hospitalization. Blood samples were collected at 6.00 a.m., 10.00 a.m., 2.00 p.m., and 7.00 p.m. on the 4th and 8th daysof hospitalization. Aggregation in response to arachidonic acid was assessed by impedance aggregometry.

Results. Lower mean platelet aggregation on pantoprazole was observed on the 8th day of hospitalization(p = 0.03). A cross-time analysis of platelet aggregation demonstrated statistical significance at two hoursand six hours after co-administration of pantoprazole and antiplatelet agents, with the highest absolutedifference observed two hours after drugs ingestion. No significant differences in aggregation betweenstudy groups were observed on the 4th day of hospitalization. No influence of CYP2C19 polymorphismon the antiplatelet effect of aspirin was observed.

Conclusions. Co-administration of pantoprazole enhances the antiplatelet effect of enteric-coated aspirinin patients with ACS.

Abstract

Background. Proton pump inhibitors (PPI) are recommended for patients receiving antiplatelet therapy.Several studies have revealed that PPI may attenuate the antiplatelet effect of ASA. However, our pilot study has indicated a positive interaction between pantoprazole and enteric-coated aspirin.The aim of the current study was to confirm that pantoprazole enhances the antiplatelet effect ofenteric-coated aspirin in patients with acute coronary syndrome (ACS) treated with dual antiplatelettherapy. Moreover, the influence of CYP2C19 polymorphism on the antiplatelet effect of aspirinwas assessed.

Material and methods. Ninety three consecutive ACS patients were prospectively enrolled in a randomized, crossover, open-labeled study. Forty four patients were given orally 40 mg of pantoprazole for the initial fourdays while the remaining forty nine were treated with pantoprazole from the 5th to the 8th day of hospitalization. Blood samples were collected at 6.00 a.m., 10.00 a.m., 2.00 p.m., and 7.00 p.m. on the 4th and 8th daysof hospitalization. Aggregation in response to arachidonic acid was assessed by impedance aggregometry.

Results. Lower mean platelet aggregation on pantoprazole was observed on the 8th day of hospitalization(p = 0.03). A cross-time analysis of platelet aggregation demonstrated statistical significance at two hoursand six hours after co-administration of pantoprazole and antiplatelet agents, with the highest absolutedifference observed two hours after drugs ingestion. No significant differences in aggregation betweenstudy groups were observed on the 4th day of hospitalization. No influence of CYP2C19 polymorphismon the antiplatelet effect of aspirin was observed.

Conclusions. Co-administration of pantoprazole enhances the antiplatelet effect of enteric-coated aspirinin patients with ACS.

Get Citation
About this article
Title

Enhanced antiplatelet effect of enteric- -coated acetylsalicylic acid in co-administration with pantoprazole

Journal

Medical Research Journal

Issue

Vol 1, No 1 (2013)

Article type

Original article

Pages

5-11

Published online

2013-07-11

Page views

719

Article views/downloads

1763

Bibliographic record

Folia Medica Copernicana 2013;1(1):5-11.

Authors

Michał Kasprzak
Marek Koziński
Katarzyna Stankowska
Joanna Boinska
Katarzyna Linkowska
Wioleta Stolarek
Agata Marciniak
Tomasz Fabiszak
Eliano Pio Navarese
Jacek Budzyński
Leszek Popiołek
Tomasz Grzybowski
Danuta Rość
Grzegorz Grześk
Przemysław Paciorek
Jacek Kubica

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl